Entries |
Document | Title | Date |
20080206260 | Chimeric Tbp-toxin proteins as mucosal adjuvants for vaccination against neisseriae - Chimeric fusion proteins comprising | 08-28-2008 |
20080213285 | SECRETED CHLAMYDIA POLYPEPTIDES, POLYNUCLEOTIDES CODING THEREFOR, THERAPEUTIC AND DIAGNOSTIC USES THEREOF - The present invention relates to secreted | 09-04-2008 |
20080317762 | Bacterial Contact Inhibition and Methods Therefor - Contemplated compositions and methods relate to bacterial contact inhibition that is conferred by two gene products, CdiA and CdiB, which are encoded by the genes cdiA and cdiB, respectively. A further gene product CdiI, encoded by the gene cdiI confers immunity to contact inhibition caused by CdiAB. | 12-25-2008 |
20090022736 | Monoclonal Antibodies That Specifically Bind To And Neutralize Bacillus Anthracis Toxin, Compositions, And Methods Of Use - The invention features compositions relating to antibodies that specifically bind to the protective antigen of | 01-22-2009 |
20090047293 | Compositions Comprising Yersinia Pestis Antigens - Disclosed are several | 02-19-2009 |
20090053237 | USE OF PENICILLIN-BINDING PROTEINS OR POLYNUCLEOTIDES OR ANTIBODIES THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS - The present invention is drawn to a penicillin-binding protein expressed by | 02-26-2009 |
20090068197 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY - Methods for detecting and treating | 03-12-2009 |
20090123481 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 05-14-2009 |
20090136518 | Compositions and methods to reduce mutagenesis - The present invention provides methods and compositions for said inhibition of drug resistance. In one embodiment, said invention provides methods and compositions for said inhibition of antibiotic resistance. The invention generally involves said administration of achaogens, agents that inhibit said mutational process, to inhibit said evolution of drug resistance. Also, described herein are compositions that are suitable for use as achaogens. | 05-28-2009 |
20090169568 | Antigenic Complex for the Diagnosis and Treatment of Porphyromonas Gingivalis Infection - The present invention provides a purified multimeric complex form | 07-02-2009 |
20090214570 | METHODS AND COMPOSITIONS FOR IMMUNIZING AGAINST CHLAMYDIA INFECTION - The present invention relates, in part, to methods and compositions for immunizing against infection by | 08-27-2009 |
20090220525 | Novel Bacterium and Vaccine - The present invention relates to a novel rod-shaped pleiomorphic non-motile Gram-negative bacterium causing a new, deadly, disease in fish, to a microbiological culture comprising said bacterium, to a vaccine comprising said bacterium and methods for the preparation of such a vaccine, to antibodies reactive with said bacterium, to diagnostic test kits and to the use of said bacterium. | 09-03-2009 |
20100021477 | DESIGN AND GENERATION OF HUMAN DE NOVO pIX PHAGE DISPLAY LIBRARIES - Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies. | 01-28-2010 |
20100055112 | Enterococcus faecalis and/or Enterococcus faecium antigen - The present invention generally relates to the field of detecting and preventing infectious diseases caused by | 03-04-2010 |
20100068214 | Identification of Candidate Vaccine Antigens from Dichelobacter Nodosus - This invention relates to a prophylactic and/or therapeutic treatment of footrot, and in particular to a vaccine effective in prophylactic and/or therapeutic treatment of footrot. Specific polypeptides of | 03-18-2010 |
20100136027 | Methods and Compositions for Treating Bacterial Infection - The present invention relates to methods and compositions for the treatment of bacterial infection, for example extraintestinal | 06-03-2010 |
20100166770 | ANTAGONISTS OF BACTERIAL SEQUENCES - The present invention refers to antagonist molecules, particularly nucleic acid effector molecules directed against a bacterial RNA. | 07-01-2010 |
20100166771 | Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae - The invention relates to the polynucleotide sequence of a nontypeable stain of | 07-01-2010 |
20100172918 | NOVEL LYSIN PROTEIN HAVING BROAD ANTIBACTERIAL ACTIVITY SPECIFIC TO BACTERIA - The present invention relates to a lysin protein originated from bacteriophage, more precisely a lysin protein comprising the amino acid sequence represented by SEQ. ID. NO: 2 which has no harm to human and animals comprising eukaryotic cells owing to its specificity to bacteria and has broad antibacterial activity, and a pharmaceutical composition for the prevention and treatment of infectious disease caused by bacteria comprising the said lysin protein as an active ingredient. | 07-08-2010 |
20100239594 | Compositions and methods for production of immunoglobulins - Provided are oligonucleotides for isolating human antibody cDNAs from cells or cell lines, such as hybridomas. The invention also provides cDNAs that encode at least one provided CDR of a heavy chain or a light chain of a human monoclonal antibody that binds to | 09-23-2010 |
20100239595 | EQUINE ANTIBODIES AGAINST BACILLUS ANTHRACIS FOR PASSIVE IMMUNIZATION AND TREATMENT - Disclosed are compositions and methods for treating a subject infected with | 09-23-2010 |
20100255002 | Immunogenic compositions for chlamydia trachomatis - The invention relates to compositions comprising combinations of | 10-07-2010 |
20100260777 | TREATMENT AND/OR PREVENTION OF SEPSIS USING AN ENTERAL COMPOSITION - Treatment and/or prevention of sepsis using an enteral composition containing phospholipids, triglycerides and cholesterol or precursors thereof. With the composition of the invention the natural level of chylomicrons is maintained, in particular in gut associated lymphoid tissue (GALT), which ensures that most of LPS and/or LTA which are released in the body can be neutralized, substantially decreasing the risk of locally occurring high levels of LPS and/or LTA and thus sepsis. | 10-14-2010 |
20100291104 | BORDETELLA OUTER-MEMBRANE PROTEIN ANTIGENS AND METHODS OF MAKING AND USING THE SAME - An isolated protein or peptide selected from the group consisting of | 11-18-2010 |
20100303830 | PREVENTION AND TREATMENT OF OTITIS MEDIA USING IgA ENRICHED MILK - This invention relates to a composition suitable for use in the prevention or treatment of otitis media comprising IgA derived from mature bovine milk and having specificity for at least one of | 12-02-2010 |
20100303831 | Methods For The Treatment Of An Infectious Bacterial Disease With An Anti-Lactone Or Lactone Derived Signal Molecules Antibody - The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant. | 12-02-2010 |
20110014210 | CHLAMYDIA VACCINE - Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a | 01-20-2011 |
20110081357 | Chimeric Vaccine for Haemophilus Influenzae-Induced Disease - The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention. | 04-07-2011 |
20110081358 | ANTIGENIC COMPLEX FOR THE DIAGNOSIS AND TREATMENT OF PORPHYROMONAS GINGIVALIS INFECTION - The present invention provides a purified multimeric complex from | 04-07-2011 |
20110104179 | PROTEASE INHIBITORY PEPTIDES - The present invention relates to compounds, peptides, peptidomimetics and pharmaceutical compositions that inhibit protease activity, and the use of these compounds, peptides, peptidomimetics and pharmaceutical compositions comprising them to treat or prevent a condition. In particular the condition may be periodontal disease. The compounds, peptides and peptidomimetics may be obtained from various caseins, for example α-casein, β-casein and κ-casein. The protease activity which the compounds, peptides, peptidomimetics and pharmaceutical compositions of the invention inhibit includes that of the gingipains. | 05-05-2011 |
20110171235 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-14-2011 |
20110171236 | ANTHRAX AND SMALL POX REPLIKINS AND METHODS OF USE - Isolated peptides of the | 07-14-2011 |
20110189196 | METAL-CITRATE TRANSPORTER ANTIGEN FROM STREPTOMYCES COELICOLOR AND USES THEREOF - The present invention relates to an isolated antigen from | 08-04-2011 |
20110189197 | Antibodies Against Protective Antigen - The present invention relates to antibodies and related molecules that specifically bind to protective antigen of | 08-04-2011 |
20110200614 | ANTHRAX SPECIFIC ANTIBODIES - The present invention is directed to diagnostic tools and therapies using antibodies to | 08-18-2011 |
20110206692 | CONFORMERS OF BACTERIAL ADHESINS - The invention relates to isolated or purified bacterial adhesin conformers, preferably with improved stability and/or immunogenicity. In a preferred aspect, the invention comprises an isolated bacterial adhesin conformer F. Also provided are methods of isolation and/or separation of such adhesin conformers. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other bacterial antigens to provide therapeutic compositions with broader range. | 08-25-2011 |
20110206693 | LYSINE RIBOSWITCH AND COMPOSITIONS AND USES THEREOF - Embodiments herein provide for lysine riboswitches and analogs thereof, and methods for using the same. In certain embodiments, test compounds are identified that associate with lysine riboswitches. In other embodiments, test compounds found to associate with lysine can be used to increase or decrease gene expression of Gram-negative bacterial organisms. | 08-25-2011 |
20110236399 | COMPOSITIONS AND METHODS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTION - This invention is directed to compositions and methods for treating (e.g., prophylactically and/or therapeutically) infection in a preterm infant. In particular, the invention provides anti-lipoteichoic acid (LTA) antibody compositions and methods of administering the same to a preterm infant (e.g., a low birth weight preterm infant (e.g., a very low birth weight preterm infant)) under conditions to establish anti-LTA antibody serum concentrations effective to kill and/or prevent growth of bacteria (e.g., Staphylococci). Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine) and research applications. | 09-29-2011 |
20120045457 | NONTYPABLE HAEMOPHILUS INFLUENZAE ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable | 02-23-2012 |
20120164156 | Recombinant F1-V Plague Vaccine - Disclosed herein is a method of inducing an immunological response in a subject which comprises administering an immunogenic amount of a purified fusion protein comprising all or part of F1 antigen of | 06-28-2012 |
20120177663 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-12-2012 |
20120189640 | Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity - Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed. | 07-26-2012 |
20120301480 | H. PYLORI LIPOPOLYSACCHARIDE OUTER CORE EPITOPE - Dextrans produced by lactic acid bacteria | 11-29-2012 |
20130004510 | VACCINE - Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein. | 01-03-2013 |
20130058953 | CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation. | 03-07-2013 |
20130189280 | PROTEIN DOMAINS AND USES THEREFOR - The present disclosure relates generally to a structure-modeling approach to identify therapeutic and diagnostic targets on proteins. Means are provided to generate agents which bind and optionally antagonize a particular domain within a protein referred to as a Cleaved_Adhesin Family Domain. In an embodiment, the disclosure is directed to the control of | 07-25-2013 |
20130216553 | Compositions and Methods for Modulation and Detection of Immune and Inflammatory Responses - A method for detecting an inflammatory or an autoimmune condition, comprising analyzing bacterial lipids, such as phosphorylated dihydroceramides (PDHC), in a sample; and, comparing results of the analysis of the bacterial lipids in the sample with information on occurrence of the bacterial lipids in a comparable sample, wherein the comparison is indicative of the inflammatory or the autoimmune condition. An example of the autoimmune condition is multiple sclerosis. According to one embodiment, an increased ratio of phosphoglycerol dihydroceramide (PG DHC) to phosphoethanolamine dihydroceramide (PE DHC) in a blood sample indicates a presence of MS in the source patient. The use of PDHCs as biomarkers for detection of MS is described. Antibodies specific to PG DHC or PE DHC are also provided, along with their uses. Also provided are compositions comprising bacteria-originated lipids useful for modulation of immune responses or TLR pathways in humans, animals, and human or animal cells or tissues. | 08-22-2013 |
20130273074 | Methods and Compositions Using Anti-LPS Ligands for the Treatment and Prevention of Inflammatory Disorders - The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of inflammatory disorders. More particularly, the invention relates to the use of methods and compositions for the treatment and prevention of disorders associated with inflammation of alimentary tract, such as human immunodeficiency virus (HIV) infection and ulcerative colitis and Crohn's disease. | 10-17-2013 |
20140037649 | DIAGNOSTIC AND/OR SCREENING AGENTS AND USES THEREFOR - Disclosed are methods and apparatus for diagnosis, detection of host response, monitoring, treatment or management of sepsis, infection-negative systemic inflammatory response syndrome (SIRS) and post-surgical inflammation in mammals. More particularly, the present invention discloses marker genes and their splice variant transcripts as well as their expression products, which are useful for distinguishing between sepsis and infection-negative SIRS, including post-surgical inflammation, and to the use of these markers in grading, monitoring, treatment and management of these conditions. | 02-06-2014 |
20140050741 | SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PROPHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS - The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection. | 02-20-2014 |
20140112937 | USE OF AN AGENT CONSISTING OF ANTIBODIES AND/OR INSULIN-LIKE GROWTH FACTOR ANTAGONISTS - The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases. | 04-24-2014 |
20140170164 | Yersinia spp. Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 06-19-2014 |
20140193429 | METAL-CITRATE TRANSPORTER ANTIGEN FROM STREPTOMYCES COELICOLOR AND USES THEREOF - The present invention relates to an isolated antigen from | 07-10-2014 |
20140271670 | COMPOSITIONS FOR TREATING SKIN DISORDERS - Compositions and methods for treating skin disorders including acne vulgaris are disclosed. The composition comprises a neutralizing agent directed against the organism and derivatives associated with the skin disorder, a synergistic agent selected from the group consisting of anti-acne actives, anti-microbial actives, antifungal actives, anti-inflammatory actives, exfoliating agents and mixtures thereof; and a pharmaceutically acceptable carrier. | 09-18-2014 |
20150010579 | Treatment and Prevention of Gardnerella Vaginalis Infections - The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from | 01-08-2015 |
20150023983 | RECOMBINANT VAPA AND VAPC PEPTIDES AND USES THEREOF - The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a | 01-22-2015 |
20150030613 | TREATMENT OF MUCOSITIS WITH IMMUNOGLOBULIN - The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis. | 01-29-2015 |
20150050292 | Detection, prevention, and treatment of Anthrax and other infectious diseases - Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against | 02-19-2015 |
20150050293 | FLAGELLUM AND ANTI-FLAGELLUM ANTIBODY LEVELS IN SAMPLES AS A DIAGNOSTIC BIOMARKER AND THERAPEUTIC TARGET FOR METABOLIC SYNDROME - High levels of bacterial flagella in a sample such as a gastrointestinal sample and/or low levels of anti-flagella antibodies serve as an indication for metabolic syndrome (such as insulin resistance, hypertension, elevated cholesterol, increased risk for blood clotting, and obesity) with highest levels of adiposity. An intervention that reduces the level and/or activity of flagella in the gastrointestinal tract can mitigate the severity of metabolic syndrome or in protecting against the development of metabolic syndrome. | 02-19-2015 |
20150110806 | CD147 AS RECEPTOR FOR PILUS-MEDIATED ADHESION OF MENINGOCOCCI TO VASCULAR ENDOTHELIA - The present invention concerns the use of an inhibitor of an interaction between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147. | 04-23-2015 |
20150307597 | ANTI-CAMPYLOBACTER JEJUNI ANTIBODIES AND USES THEREFOR - is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to | 10-29-2015 |
20160022794 | SIDEROPHORE-BASED IMMUNIZATION AGAINST GRAM-NEGATIVE BACTERIA - The present invention provides novel enterobactin-carrier protein conjugates and salmochelin-carrier protein conjugates, such as compounds of Formula (I), and salts thereof. The present invention also provides compositions, kits, and methods that involve the compounds of Formula (I) and are useful in inducing an immune response, treating a bacterial infection and/or inflammatory bowel disease in a subject, preventing a bacterial infection and/or inflammatory bowel disease in a subject, or inhibiting the growth of or killing a bacterium. | 01-28-2016 |
20160074498 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF Ebp PILUS-RELATED DISEASES - The present invention relates to compositions comprising EbpA and methods of use thereof. Specifically, methods useful in the treatment and prevention of EbpA-associated infections. | 03-17-2016 |
20160158333 | METHODS FOR PRODUCING SALMONELLA O-ANTIGEN CAPSULES, COMPOSITIONS AND USES THEREOF - Methods of purifying O-Ag capsules from an | 06-09-2016 |